Lilly’s long-acting insulin wins NICE blessing ahead of potential UK approval
For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be…
Novo Nordisk launches once-weekly insulin Awiqli in US market
Danish pharmaceutical company ‘Novo Nordisk’ has launched a once-weekly insulin injection in the US market. EPA/MARTIN DIVISEK/Yonhap News…
Novo Nordisk’s India Insulin Push and Aggressive Buyback Counterbalance a Pipeline Jolt
Novo Nordisk ended the week at €43.32, a 1.29% gain on Friday that masked a slightly negative weekly…
Novo Nordisk Forges Ahead with Oral Wegovy and Weekly Insulin Amid CagriSema Device Study Withdrawal
Novo Nordisk is executing a multi-front strategy to defend its dominance in the obesity and diabetes markets, rolling…
Novo Nordisk Rolls Out Oral Wegovy and Weekly Insulin on Same Day as Supply Chain Hiccups Emerge
Novo Nordisk unleashed a flurry of product launches on July 10, 2026, putting the oral version of Wegovy…
Novo Nordisk Launches World’s First Once-Weekly Insulin In India
One injection a week instead of one every day. Danish drugmaker Novo Nordisk has launched Awiqli, or insulin…
Novo Nordisk launches world’s first once-weekly basal insulin in India at Rs 3.71 per unit
Novo Nordisk launches world’s first once-weekly basal insulin in India at Rs 3.71 per unit July 09, 2026…
Novo Nordisk launches once-weekly insulin Awiqli in India for type 1 and type 2 diabetes
Danish drugmaker Novo Nordisk on Thursday, July 9, launched its once-weekly basal insulin injection, Awiqli, in India, as…
Novo Nordisk receives FDA approval for basal insulin Awiqli
Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700…
Novo Nordisk wins FDA approval for insulin injection for type 2 diabetes
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection…
Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Novo Nordisk A/S Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli®…
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type…